Buprenorphine is available under several brand names, with Suboxone being the most widely recognized. Suboxone is a combination medication that includes buprenorphine and naloxone, used primarily for the treatment of opioid use disorder and moderate to severe pain [1].
What are the different brand names for buprenorphine?
Beyond Suboxone, other buprenorphine-containing medications exist. Buprenorphine alone is available as a generic medication. Brands specifically for pain management include Belbuca, a buccal film, and Butrans, a transdermal patch [2]. For opioid use disorder, Subutex was previously available as buprenorphine alone but has largely been superseded by combination products like Suboxone [3].
How do Suboxone and other buprenorphine brands work?
Buprenorphine is a partial opioid agonist. This means it binds to opioid receptors in the brain but activates them less strongly than full agonists like heroin or morphine. This mechanism helps to reduce cravings and withdrawal symptoms associated with opioid use disorder without causing the same level of euphoria or respiratory depression [4]. The addition of naloxone in formulations like Suboxone is an abuse-deterrent measure; if the medication is injected, the naloxone can precipitate withdrawal symptoms [1].
When do patents for buprenorphine products expire?
Patent expiration dates are crucial for the availability of generic alternatives. For example, significant patents related to the original Suboxone film formulation have expired, leading to the introduction of generic versions [5]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including buprenorphine products, which can indicate when market exclusivity is expected to end and generic competition may begin [6]. Specific patent expiry dates can vary based on the particular formulation and patent protection in different regions.
What are the risks and side effects associated with buprenorphine brands?
Common side effects of buprenorphine include headache, nausea, vomiting, sweating, and constipation [2]. More serious risks, though less common, can include respiratory depression, especially when used with other central nervous system depressants, and liver problems [4]. The naloxone component is designed to mitigate the risk of misuse, but non-adherence to prescribed usage can still lead to adverse events [1].
Can generic buprenorphine products enter the market?
Yes, generic versions of buprenorphine products can enter the market after the relevant patents expire and regulatory approval is obtained. The availability of generic Suboxone, for instance, has increased competition and potentially reduced costs for patients and healthcare systems [5].
Who manufactures buprenorphine brands?
The original brand-name manufacturer of Suboxone was Reckitt Benckiser (now Indivior) [3]. Generic versions of buprenorphine and buprenorphine/naloxone products are manufactured by various pharmaceutical companies that specialize in generic drug production. Belbuca is manufactured by BioDelivery Sciences, and Butrans was developed by Dornier Machinery GmbH and is marketed by various companies [2].
How is buprenorphine prescribed and regulated?
Buprenorphine, particularly for opioid use disorder, is a Schedule III controlled substance in the United States. Prescribers must have a specific waiver (previously a DEA X-waiver, now integrated into standard DEA registration) to dispense or prescribe it for addiction treatment [7]. Its use is regulated by the Food and Drug Administration (FDA) to ensure safety and efficacy.
---
Sources:
[1] U.S. Food & Drug Administration. (n.d.). FDA approves first generic version of Suboxone sublingual film. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suboxone-buprenorphine-and-naloxone-sublingual-film-information
[2] National Institute on Drug Abuse. (2023, June). Buprenorphine Treatment for Opioid Use Disorder. Retrieved from https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-use-disorder-OUD/buprenorphine
[3] DrugPatentWatch.com. (n.d.). Suboxone. Retrieved from https://www.drugpatentwatch.com/en/drug/suboxone
[4] Substance Abuse and Mental Health Services Administration. (n.d.). Medications for Opioid Use Disorder. Retrieved from https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/medications-opioid-use-disorder
[5] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/drugthedoc/
[6] DrugPatentWatch.com. (n.d.). Buprenorphine. Retrieved from https://www.drugpatentwatch.com/en/search?q=buprenorphine
[7] U.S. Drug Enforcement Administration. (n.d.). DEA Schedules and Regulations. Retrieved from https://www.dea.gov/